Next Generation Flow™ for Immunology
Diagnosis and monitoring of Primary Immunodeficiencies (PIDs)
Key Facts
About Cytognos
Cytognos is a private, revenue-generating diagnostics company with over two decades of experience in the flow cytometry market. The company's core strategy involves licensing and commercializing innovative technologies from academic consortia, most notably the EuroFlow™ consortium, to address gaps in multicolor flow cytometry workflows. Its flagship offerings include the Next Generation Flow™ standardized testing approach and the Infinicyt™ software, targeting improved diagnosis and monitoring of hematological malignancies and immunodeficiencies. Cytognos maintains ISO 13485 and ISO 9001 certifications, underscoring its commitment to quality in the medical device and diagnostic sectors.
View full company profile